Actively Recruiting
A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants
Led by Shanghai Huaota Biopharmaceutical Co., Ltd. · Updated on 2025-09-08
46
Participants Needed
1
Research Sites
45 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study is to investigate the safety and tolerability of HB0056 in healthy subjects following single-dose.
CONDITIONS
Official Title
A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy male or female subjects age �3E= 18 and �3C= 55 years
- Body Mass Index (BMI) �3E= 18 and �3C= 32 kg/m�b2
- Normal ECG, blood pressure, respiratory rate, temperature, and heart rate unless considered not clinically significant by the investigator
- Signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation
You will not qualify if you...
- History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease
- Current or history of malignancy
- Family history of premature Coronary Heart Disease (CHD)
- History of clinically significant opportunistic infection such as invasive candidiasis or pneumocystis pneumonia
- Pregnant or breastfeeding women or women with a positive pregnancy test
- Further exclusion criteria applied
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
New Zealand Clinical Research
Christchurch, New Zealand, 8011
Actively Recruiting
Research Team
J
Jingjing Wang
CONTACT
X
Xiaoyan Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
OTHER
Number of Arms
8
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here